Menu
Log in


Canadian Urban Substance Use Surveillance Project (CUSSP)

Funded by the Public Health Agency of Canada (PHAC)

Canada is currently experiencing the worst substance use crisis on record. The aim of the project is to assess the feasibility of and develop and implement an integrated pan-Canadian substance use surveillance system via consolidated and expanded substance use data indicators on supply, use, determinants, interventions, and outcomes to inform policy and practice and to reduce substance use-related harms in cities across the country.


Program Phases

The CUSSP project is being carried out in two phases. 

Phase 1

Phase 1 of the project focuses on a feasibility study. The specific objectives include:

a) Compile a comprehensive list of data sources and indicators relating to substance use that are currently being collected and used by different local systems across Canada.

b) Identify key stakeholders, experts, institutions actively engaged in substance use surveillance locally.

c) Design and propose an integrated public health surveillance system for substance use in urban communities across Canada.

Phase 2

The second phase, or implementation phase, will aim to pilot a comparative surveillance system model developed by the project in two urban centres: Vancouver and Saskatoon.

CUSSP started in late 2022, with Phase 1 objectives wrapping up by February 2024. Over the past year, Phase 2  incorporated a senior epidemiologist and I.T. specialist to the research team. A number of community consultations occurred and by February 2025, CUSSP Phase 2 was completed.

In Phase 1 objectives a) and b) involved an environmental scan that included a grey literature search of existing surveillance systems, stakeholder holder interviews, and a stakeholder survey. Findings were presented during the UPHN member annual gathering in Halifax in June 2023, and at the UPHN member meeting in Montreal in October 2023. 

Phase 1's last objective included a detailed report, outlining the basis for an integrated public health surveillance system, using a harm reduction approach of meeting cities "where they are at". The harm reduction approach included reorienting and modifying our approach to data collection and analysis by prioritizing urban centres and their local configurations of actors and data sources. The final Milestone report on Phase 1 included a breakdown of the substance use continuum and surveillance framework, the role of public health units, application of this framework to data assets mapping and the steps and capacity needed to launch a pilot system.

In the (final) implementation phase, two pilot sites - Vancouver and Saskatoon - were chosen, based on interest and existing relationships within their respective health authorities. These two cities reflect opposing ends of the surveillance capacity spectrum in Canada. Vancouver Coastal Health (VCH) contributed indicators currently collected on the authority of the Medical Health Officer while Saskatoon required a more adaptable approach, with multiple partners contributing data. Data was collected for 3 consecutive months and a dashboard, comprised of 21 common indicators, was created. 

Lessons learned from Phase 2 include the importance of community partner input and engagement in the system design, collection, interpretation and discussion of the data to increase synergies, communication, and service delivery. A properly-resourced surveillance system that allows local public health and service providers to compare and learn from one another, must be a critical goal.


Through the literature search, stakeholder interviews, and survey, we have identified:

  • 32 independent substances use surveillance systems across 9 provinces including Alberta, British Columbia, New Brunswick, Nova Scotia, Manitoba, Ontario, Prince Edward Island, Saskatchewan, and Quebec.
  • Over 17 substances including (Fentanyl, Fentanyl analogue, Hydromorphone, morphine, codeine, oxycodone, heroin, methadone, methamphetamine, cocaine, benzodiazepines, benzodiazepine analogues, 3,4-Methylenedioxymethamphetamine (MDMA), Tramadol, Ketamine, Alcohol, Other sedatives, Cannabis, Nitazene, Carfentanyl, and Xylazine) are actively being monitored across Canadian jurisdictions. Two-third of these substances are currently monitored by all 9 jurisdictions surveyed.
  • 16 different data sources are currently in use to provide data on substance use. These data sources span provincial and local public health jurisdictions.
  • Majority of current data sources provide substance use outcome-related indicators.
  • There are limited socio-demographic data being collected or accessible across these systems.
  • There are innovative data sources like wastewater being integrated in some jurisdictions.
  • There are multiple stakeholder collaborative platforms at local and provincial jurisdictions.

Future Prospects for CUSSP

  •  With funds, an intention of the project is for incremental growth to allow for more cities to be included in the (sentinel) surveillance system.
  • Continue to engage with the advisory council to provide the necessary expertise, support, and network required for this project.
  • Assess the level of data comparability across stakeholders engaged in substance use surveillance.
  • Attention to creating disclosure of information agreements to allow for heightened access for community partners working in harm reduction services.
  • Propose possible pathways towards a pan Canadian substance use surveillance system.
  • Dashboards are popular visual tools for understanding health data and trends. A dashboard that displays both historical and real-time information at the local level is desperately needed for addressing substance use harms in urban centres in Canada.
Powered by Wild Apricot Membership Software